1. Pink Sheet

REMS Vendor Disruptions Prompt Greater US FDA Scrutiny

 
• By Brenda Sandburg

McKesson’s exit from the space forced sponsors to switch vendors managing their REMS programs, which in some instances affected patient access to drugs. Omnibus legislation requires GAO report and collection of public input on factors FDA should consider in reviewing vendor changes.

Vendor
Switching third-party vendors that manage REMS programs can disrupt patient access to a drug • Source: Shutterstock

The third-party vendors who manage Risk Evaluation and Mitigation Strategy (REMS) programs for drug sponsors mostly operate behind the scenes without public attention. But a provision inserted into the omnibus government funding bill indicates that problems in the space after some sponsors switched vendors may pave the way for more open FDA oversight.

The provision requires opening a public docket to seek comments on factors that the FDA should consider when reviewing requests...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

More from Pink Sheet

What Pharma Needs To Know About Vietnam’s Drug Registration Reforms

 
• By Neena Brizmohun

Newly introduced rules for streamlining drug registration in Vietnam are said to present both opportunities and challenges for stakeholders.

European Industry Calls For Support As It Juggles Multiple Challenges

 
• By Dave Wallace

At Medicines for Europe’s legal and annual conferences in Brussels last week, multiple key issues competed for attention, giving the generics and biosimilars industry plenty to think about at a critical time for EU pharma reform.

England’s NHS Plan Eyes Cancer Vaccine Boost, Single Formulary & ‘Pay For Impact’ Drug Deal

 
• By Eliza Slawther

The creation of a single national formulary for medicines prescribing that could impact industry is among the action points in the UK government’s new 10-year health plan for the National Health Service in England.